| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 10/21/2026 | ±2.6% | +4.3% | under-priced |
| 07/21/2026 | ±2.2% | -11.0% | under-priced |
| 04/21/2026 | ±1.9% | -0.5% | over-priced |
| 02/24/2026 | ±2.9% | -0.8% | over-priced |
| 10/21/2025 | ±2.3% | +5.9% | under-priced |
| 07/22/2025 | ±2.5% | +1.0% | over-priced |
| 04/22/2025 | ±3.0% | +3.8% | under-priced |
| 02/20/2025 | ±2.3% | +1.4% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $1.75 | $6.6B | $1.2B |
| Q2 FY2026 | $1.23 | $6.3B | $870M |
| Q1 FY2026 | $1.45 | $6.0B | $1.0B |
| Q4 FY2025 | — | $6.8B | $1.2B |
DHR (DHR) reports in 85 days, with the next report estimated for 01/20/2027. Across the last 8 reports, options priced an average ±2.5% earnings move while the stock actually moved 3.6% on average — the market has been roughly fair on DHR's earnings risk. Fundamentals into the print: EPS up 37.8% year-over-year, revenue up 8.3%. QuantLogix's live 5-factor engine currently reads DHR as a buy at 87/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →